Covenant Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.02M | Sell |
19,947
-1,311
| -6% | -$282K | 0.84% | 37 |
|
|
2026
Q1 | $4.62M | Sell |
21,258
-186
| -0.9% | -$41.3K | 0.7% | 49 |
|
|
2025
Q4 | $4.9M | Sell |
21,444
-329
| -2% | -$74.9K | 0.58% | 40 |
|
|
2025
Q3 | $5.04M | Sell |
21,773
-149
| -0.7% | -$30.3K | 0.57% | 43 |
|
|
2025
Q2 | $4.07M | Sell |
21,922
-206
| -0.9% | -$38.3K | 0.6% | 45 |
|
|
2025
Q1 | $4.64M | Sell |
22,128
-1,366
| -6% | -$266K | 1.02% | 35 |
|
|
2024
Q4 | $4.17M | Sell |
23,494
-1,276
| -5% | -$235K | 0.64% | 44 |
|
|
2024
Q3 | $4.89M | Sell |
24,770
-970
| -4% | -$181K | 0.77% | 40 |
|
|
2024
Q2 | $4.41M | Sell |
25,740
-97
| -0.4% | -$16.1K | 0.7% | 39 |
|
|
2024
Q1 | $4.7M | Buy |
25,837
+1,220
| +5% | +$210K | 0.77% | 37 |
|
|
2023
Q4 | $3.81M | Sell |
24,617
-1,266
| -5% | -$185K | 0.69% | 39 |
|
|
2023
Q3 | $3.86M | Sell |
25,883
-76
| -0.3% | -$11.2K | 1.02% | 27 |
|
|
2023
Q2 | $3.5M | Sell |
25,959
-6
| -0% | -$880 | 0.89% | 41 |
|
|
2023
Q1 | $4.14M | Buy |
25,965
+727
| +3% | +$111K | 0.98% | 30 |
|
|
2022
Q4 | $4.08M | Buy |
25,238
+491
| +2% | +$75.3K | 0.97% | 32 |
|
|
2022
Q3 | $3.32M | Buy |
24,747
+75
| +0.3% | +$10.8K | 0.95% | 29 |
|
|
2022
Q2 | $3.78M | Buy |
24,672
+239
| +1% | +$36.5K | 1.2% | 23 |
|
|
2022
Q1 | $3.96M | Sell |
24,433
-85
| -0.3% | -$12.3K | 1.07% | 28 |
|
|
2021
Q4 | $3.32M | Sell |
24,518
-93
| -0.4% | -$11K | 0.88% | 35 |
|
|
2021
Q3 | $2.65M | Sell |
24,611
-274
| -1% | -$31.3K | 0.79% | 41 |
|
|
2021
Q2 | $2.8M | Hold |
24,885
| – | – | 0.83% | 40 |
|
|
2021
Q1 | $2.69M | Buy |
24,885
+325
| +1% | +$34.8K | 0.84% | 46 |
|
|
2020
Q4 | $2.63M | Buy |
24,560
+1,035
| +4% | +$99.5K | 0.87% | 40 |
|
|
2020
Q3 | $2.06M | Buy |
23,525
+585
| +3% | +$55.1K | 0.66% | 46 |
|
|
2020
Q2 | $2.25M | Buy |
22,940
+283
| +1% | +$24.9K | 0.5% | 45 |
|
|
2020
Q1 | $1.73M | Buy |
22,657
+1,251
| +6% | +$107K | 0.52% | 46 |
|
|
2019
Q4 | $1.9M | Sell |
21,406
-140
| -0.6% | -$11.6K | 0.83% | 43 |
|
|
2019
Q3 | $1.63M | Sell |
21,546
-250
| -1% | -$17.1K | 0.82% | 46 |
|
|
2019
Q2 | $1.58M | Buy |
21,796
+220
| +1% | +$17.3K | 0.82% | 44 |
|
|
2019
Q1 | $1.74M | Sell |
21,576
-922
| -4% | -$75.4K | 0.91% | 40 |
|
|
2018
Q4 | $2.13M | Hold |
22,498
| – | – | 1.07% | 29 |
|
|
2018
Q3 | $2.13M | Sell |
22,498
-495
| -2% | -$46.9K | 1.07% | 29 |
|
|
2018
Q2 | $2.13M | Buy |
22,993
+355
| +2% | +$34.7K | 1.15% | 24 |
|
|
2018
Q1 | $2.14M | Buy |
22,638
+272
| +1% | +$29.9K | 1.24% | 24 |
|
|
2017
Q4 | $2.16M | Buy |
22,366
+243
| +1% | +$22.9K | 1.26% | 22 |
|
|
2017
Q3 | $1.97M | Buy |
22,123
+680
| +3% | +$51.8K | 1.2% | 26 |
|
|
2017
Q2 | $1.55M | Hold |
21,443
| – | – | 1% | 35 |
|
|
2017
Q1 | $1.4M | Buy |
21,443
+301
| +1% | +$18.9K | 0.94% | 36 |
|
|
2016
Q4 | $1.32M | Buy |
+21,142
| New | +$1.29M | 0.89% | 41 |
|
Other funds holding ABBV
Covenant Asset Management's ABBV Position: Q2 2026 in Review
Covenant Asset Management reduced its AbbVie (ABBV) stake by 6.2% in Q2 2026, selling an estimated $282K and leaving 19,947 shares worth $5.02M. The position accounts for 0.84% of the portfolio, ranked #37.
Covenant Asset Management first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. The position peaked at $5.04M in Q3 2025. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Covenant Asset Management held 19,947 shares of AbbVie worth $5.02M as of Q2 2026.
- Covenant Asset Management sold 1,311 AbbVie shares in Q2 2026, an estimated $282K.
- AbbVie made up 0.84% of Covenant Asset Management's portfolio in Q2 2026, its #37 holding.
- Covenant Asset Management first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- Covenant Asset Management's AbbVie position peaked at $5.04M in Q3 2025.
- 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Covenant Asset Management's 13F filing for Q2 2026, filed 20 Jul 2026.